FDA-Approved Pediatric Indications for Abilify (Aripiprazole)
Abilify is FDA-approved in pediatric patients for four specific diagnoses: irritability associated with autism spectrum disorder (ages 6-17), bipolar I disorder (ages 10-17), schizophrenia (ages 13-17), and Tourette's disorder (ages 6-18). 1
Primary FDA-Approved Indications
1. Irritability Associated with Autism Spectrum Disorder (Ages 6-17)
- Target symptoms: irritability, hyperactivity, stereotypy, social withdrawal, and inappropriate speech
- Demonstrated 56% positive response rate at 5 mg dose versus 35% on placebo 2
- Significant improvements in Irritability, Hyperactivity, and Stereotypy subscales 2
- Dosing: 5-15 mg/day flexibly dosed 2
2. Bipolar I Disorder (Ages 10-17)
- Approved for both acute manic/mixed episodes and maintenance treatment
- Both 10 mg/day and 30 mg/day doses showed superiority to placebo up to 30 weeks 3
- Time to all-cause discontinuation was significantly longer: 15.6 weeks (10 mg), 9.5 weeks (30 mg) versus 5.3 weeks (placebo) 3
- Clinical caveat: Completion rates were low across all treatment arms, reflecting the challenging nature of pediatric bipolar disorder 3
3. Schizophrenia (Ages 13-17)
- Supported by controlled trial evidence in adolescents 1, 4
- Part of the broader evidence base for psychotic disorders in youth 4
4. Tourette's Disorder (Ages 6-18)
- Included in FDA-approved pediatric indications 1, 4
- Supported by open-label evidence for tic disorders 5
Important Safety Considerations
Most Common Adverse Effects in Pediatrics (≥10%)
The pediatric adverse effect profile differs from adults 1:
- Somnolence
- Headache
- Vomiting
- Extrapyramidal disorder
- Fatigue
- Increased appetite
- Insomnia
- Nausea
- Nasopharyngitis
- Weight gain (particularly concerning in children <12 years) 6
Critical Monitoring Requirements
Weight and metabolic monitoring is essential, as BMI increases were statistically significant (22.5 to 24.1, p=0.003), with more pronounced changes in children younger than 12 years 6. However, aripiprazole appears to have minimal metabolic impact compared to most other atypical antipsychotics 5.
Boxed Warnings Apply
- Increased mortality in elderly patients with dementia-related psychosis (not a pediatric indication)
- Suicidal thoughts and behaviors in children, adolescents, and young adults 1
Off-Label Use Caution
While evidence exists for off-label uses including ADHD with conduct disorder 7, disruptive behavior disorders 4, and aggression in developmental disabilities 6, these are NOT FDA-approved indications and should be reserved for cases where approved treatments have failed 4, 8. The EudraVigilance database analysis revealed that approximately 90% of reported adverse events in pediatric patients were serious, with high proportions of off-label use 8.
Off-Label Evidence Shows:
- 63.1% response rate in ADHD with conduct disorder (open-label, n=19) 7
- 56% improvement in behavioral symptoms in developmental disabilities 6
- However, these lack the rigorous controlled trial evidence of approved indications 4, 8
Practical Prescribing Algorithm
For a pediatric patient, prescribe Abilify only if they have one of these four diagnoses:
- Autism spectrum disorder with significant irritability (ages 6-17)
- Bipolar I disorder, manic or mixed episode (ages 10-17)
- Schizophrenia (ages 13-17)
- Tourette's disorder (ages 6-18)
Starting approach: Begin with lower doses (2.5-5 mg) and titrate based on response, with typical maintenance doses of 5-15 mg/day 2, 6. Girls may require dose adjustments as they demonstrate 41% higher dose-corrected concentrations than boys 9.